Thomas Glanzmann to retire as Grifols Chairman and will be succeeded by Board member Anne-Catherine Berner

Barcelona, Spain, Feb. 25, 2025 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma derived medicines, today announced that its Chairman of the Board of Directors, Thomas Glanzmann, has decided not to stand for reelection at the 2025 annual general meeting (AGM) after concluding his two-year agreement to act as Executive Chairman. He will be succeeded as non-executive Chair by Grifols independent Board member Anne-Catherine Berner.

Glanzmann, who has also decided to retire from the Board after being a member for nearly 20 years, became a director in 2006, the year the company listed on the Spanish Stock Exchange. He was named Executive Chairman in February 2023 and also assumed the CEO role three months later. In April 2024, he transitioned the CEO position to Nacho Abia and became non-Executive Chairman in September.

During his long tenure, first as a Grifols Board member and Vice Chairman and then later with executive responsibilities, Glanzmann was a significant contributor to guiding Grifols through periods of growth and transformation as the company expanded internationally to become a global leader in plasma and transfusion medicine.

His steady leadership left a permanent and positive mark on the organization. From the Board, he contributed to the establishment of the company’s first Strategy Office. More recently, as Executive Chairman and CEO, he worked alongside the management team to lead the company out of the pandemic and into a year of record revenue in 2023, while taking decisive steps to lower its debt.

Glanzmann, together with the Grifols family, was critical in recruiting Abia as CEO and setting up a new leadership team that, with the support of the Board and the family, introduced significant governance changes in the company. In 2024, he enabled Grifols to work through an unprecedented short-seller attack as well as Brookfield’s potential interest in acquiring the company as it went on to deliver excellent financial results through the first nine months of the year.

“It has been an honor and privilege to Chair the Board and be CEO of this great 115-year-old company, especially during the latest challenging and transformative times,” said Glanzmann. “I am proud of the progress we have made during my stewardship, which would not have been possible without the great support of my colleagues on the Board, the Grifols family, the relentless dedication of the management team and, of course, the incredible commitment of Grifols employees to our mission of saving and improving lives. We laid the foundation for a greater future, which I know will be taken to the next level by Nacho and my Chair successor, Anne-Catherine Berner, who brings significant governance experience and a new perspective that will greatly benefit the company as it moves forward.”

Anne-Catherine Berner, an independent Board member since 2024, currently chairs the Grifols Appointment and Renumeration Committee. She currently serves on Boards in Sweden, Germany and Switzerland and is the Chairwoman of the Board, Foundation for Children’s Trauma Hospital and Institution Nadija in Helsinki. She was a Minister of Transport in Finland for four years and was also the Chairwoman and CEO of Vallila Interior AB Oy, a family-owned company in Finland.

“It is a great honor for me to be nominated to chair Grifols, an exceptional company revered for its long-time commitment to providing patients with trusted plasma medicines and other healthcare solutions,” said Anne-Catherine Berner. “I look forward to collaborating closely with Thomas over the next few months as part of the transition, and then with the rest of the Board on an ongoing basis to ensure Grifols continues on its strategic growth path and realizes its full potential for all stakeholders.”

“All of us at Grifols are very grateful that Thomas has been part of the team for almost 20 years. His advice, business vision, ethics and commitment to the safety of our products have been instrumental in building the company we have today,” said Raimon Grifols, Grifols Vice-Chairman. “His stewardship and unequaled commitment, especially during recent challenging times, have been critical in contributing to, protecting and defending the reputation we have built over our 115-year history. Thank you for everything, Thomas.”

With the appointment of an independent chairperson, the position of independent lead director will no longer be applicable. Glanzmann will remain Chairman until the 2025 AGM, after which time the company has no plans to replace the Board vacancy and the total number of Board members will be reduced to 12.